Skip to main content
Apply for Grants

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (1952${count})

  • Priority Biology, 2021
    LRRK2 Regulation of Melanoma Progression

    Study Rationale:
    People with Parkinson's disease (PD) are more likely to develop melanoma, and people with melanoma are more likely to develop PD than the general population. Additionally, melanoma...

  • , 2021
    RNA Targeting Small Molecules as Therapeutics for Parkinson’s

    Study Rationale:    
    Abnormal clumping of the protein alpha-synuclein is a hallmark of Parkinson's disease (PD) and a likely cause of neurodegeneration and, ultimately, symptoms. One of the causes...

  • , 2021
    Codevelopment of Small-molecule Regulators of Miro1 for the Treatment of Parkinson’s Disease and a GLP Clinical Biomarker Assay

    Study Rationale:    
    The mitochondrial protein Miro1 is elevated in more than 90% of all Parkinson’s disease (PD) patients of both genetic and sporadic forms. The high level of Miro1 is a pathogenic...

  • Research Grant, 2021
    Genotyping of Lymphoblastoid Cell Lines from Familial and Sporadic Parkinson’s Disease

    Study Rationale:
    Our previous studies show deficits in a cell activity called centrosome cohesion in cells from people with Parkinson’s disease (PD) and a LRRK2 mutation. These deficits are reverted by...

  • Priority Biology, 2021
    Developing New Therapeutic Drugs for Parkinson’s in Human Stem Cell Neurons

    Study Rationale:
    Neurons derived from stem cells from people with Parkinson’s disease offer an opportunity to perform drug and target discovery. We completed a screen of 4,000 drug compounds in such...

  • , 2021
    Brain-penetrating Antisense Oligonucleotide to Down-regulate Alpha-synuclein

    Study Rationale:
    Antisense oligonucleotides (ASOs) are a new type of therapeutic that have promise for treating Parkinson’s disease. They act by modifying the production of specific proteins, such as...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.